GEAP201914545A - Solid state forms of fused heteroaromatic pyrrolidinones - Google Patents

Solid state forms of fused heteroaromatic pyrrolidinones

Info

Publication number
GEAP201914545A
GEAP201914545A GEAP201914545A GEAP2019014545A GEAP201914545A GE AP201914545 A GEAP201914545 A GE AP201914545A GE AP201914545 A GEAP201914545 A GE AP201914545A GE AP2019014545 A GEAP2019014545 A GE AP2019014545A GE AP201914545 A GEAP201914545 A GE AP201914545A
Authority
GE
Georgia
Prior art keywords
solid state
state forms
fused heteroaromatic
pyrrolidinones
heteroaromatic pyrrolidinones
Prior art date
Application number
GEAP201914545A
Other languages
English (en)
Inventor
Kentaro Yaji
Tomonori Ichibakase
Naoki Yoshikawa
Hajime Motoyoshi
Chunrong Ma
Christopher Matthews
Rongliang Chen
Colin O'bryan
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEAP201914545(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of GEAP201914545A publication Critical patent/GEAP201914545A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
GEAP201914545A 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones GEAP201914545A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093564P 2014-12-18 2014-12-18
US201562115223P 2015-02-12 2015-02-12
US201562180222P 2015-06-16 2015-06-16

Publications (1)

Publication Number Publication Date
GEAP201914545A true GEAP201914545A (en) 2019-08-12

Family

ID=55299676

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP201914545A GEAP201914545A (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones
GEAP201514545A GEP20197050B (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP201514545A GEP20197050B (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones

Country Status (29)

Country Link
US (3) US10676473B2 (enExample)
EP (2) EP3677582B1 (enExample)
JP (3) JP6778195B2 (enExample)
KR (1) KR102037502B1 (enExample)
CN (1) CN107108609B (enExample)
AU (1) AU2015365580B2 (enExample)
BR (1) BR112017013149B1 (enExample)
CA (1) CA2970864C (enExample)
CL (1) CL2017001561A1 (enExample)
CO (1) CO2017005910A2 (enExample)
CR (1) CR20170249A (enExample)
DK (1) DK3233857T3 (enExample)
DO (1) DOP2017000130A (enExample)
EA (1) EA032291B1 (enExample)
EC (1) ECSP17038100A (enExample)
ES (1) ES2788454T3 (enExample)
GE (2) GEAP201914545A (enExample)
IL (1) IL252941B (enExample)
MX (1) MX373586B (enExample)
MY (1) MY199935A (enExample)
NZ (1) NZ732371A (enExample)
PE (1) PE20171179A1 (enExample)
PH (1) PH12017501123A1 (enExample)
PL (1) PL3233857T3 (enExample)
SG (1) SG11201701911QA (enExample)
TN (1) TN2017000080A1 (enExample)
UA (1) UA120632C2 (enExample)
WO (1) WO2016097862A2 (enExample)
ZA (1) ZA201701800B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032291B1 (ru) * 2014-12-18 2019-05-31 Такеда Фармасьютикал Компани Лимитед Твердые формы конденсированных гетероароматических пирролидинонов
EP3484466A1 (en) * 2016-07-13 2019-05-22 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
CN111194319A (zh) 2017-10-19 2020-05-22 拜耳动物保健有限责任公司 稠合的杂芳族吡咯烷酮类化合物用于治疗和预防动物中的疾病的用途
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
KR102874906B1 (ko) * 2018-12-14 2025-10-21 치아타이 티안큉 파마수티컬 그룹 주식회사 Syk 억제제의 염 및 이의 결정형
JP2022519383A (ja) 2019-02-07 2022-03-23 ヤンセン バイオテツク，インコーポレーテツド ジヒドロオロト酸デヒドロゲナーゼ阻害剤
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
CN114630822B (zh) 2019-10-10 2024-10-01 詹森生物科技公司 联芳基二氢乳清酸脱氢酶抑制剂
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
WO2022074534A1 (en) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
WO2022127753A1 (zh) * 2020-12-18 2022-06-23 山东轩竹医药科技有限公司 稠环类AhR抑制剂
KR20240006638A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR20240006631A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR102539612B1 (ko) 2021-12-24 2023-06-02 엘에스일렉트릭(주) IP 기반 RAPIEnet을 지원하는 통신 디바이스 및 이를 포함하는 네트워크 시스템
WO2024114664A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
EP4626427A1 (en) 2022-11-30 2025-10-08 Janssen Pharmaceutica NV Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960372B1 (en) * 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
US8440689B2 (en) * 2009-12-23 2013-05-14 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones
EP2723739B1 (en) * 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
TW201625263A (zh) * 2014-09-24 2016-07-16 千禧製藥公司 利用ＰＩ３Ｋα抑制劑與紫杉烷之組合治療
EA032291B1 (ru) * 2014-12-18 2019-05-31 Такеда Фармасьютикал Компани Лимитед Твердые формы конденсированных гетероароматических пирролидинонов

Also Published As

Publication number Publication date
AU2015365580A1 (en) 2017-07-06
AU2015365580B2 (en) 2020-04-02
MX373586B (es) 2020-05-05
PL3233857T3 (pl) 2020-07-27
EP3677582B1 (en) 2023-01-25
IL252941B (en) 2020-11-30
US20230348461A1 (en) 2023-11-02
CA2970864A1 (en) 2016-06-23
US10676473B2 (en) 2020-06-09
CL2017001561A1 (es) 2018-01-12
TN2017000080A1 (en) 2018-07-04
GEP20197050B (en) 2019-12-10
SG11201701911QA (en) 2017-04-27
DK3233857T3 (da) 2020-04-27
JP2022017477A (ja) 2022-01-25
HK1243406A1 (zh) 2018-07-13
EA201791369A1 (ru) 2017-10-31
KR102037502B1 (ko) 2019-10-28
US20160176869A1 (en) 2016-06-23
JP2017537969A (ja) 2017-12-21
KR20170095374A (ko) 2017-08-22
EP3233857A2 (en) 2017-10-25
US20200339573A1 (en) 2020-10-29
ECSP17038100A (es) 2017-12-01
CR20170249A (es) 2017-09-25
EA032291B1 (ru) 2019-05-31
IL252941A0 (en) 2017-08-31
JP6778195B2 (ja) 2020-10-28
CO2017005910A2 (es) 2017-10-20
PH12017501123A1 (en) 2017-11-27
BR112017013149B1 (pt) 2022-10-11
US11352355B2 (en) 2022-06-07
WO2016097862A2 (en) 2016-06-23
UA120632C2 (uk) 2020-01-10
ZA201701800B (en) 2020-05-27
EP3233857B1 (en) 2020-03-11
DOP2017000130A (es) 2017-07-15
BR112017013149A2 (pt) 2018-04-10
CN107108609B (zh) 2020-02-18
WO2016097862A3 (en) 2016-08-11
MY199935A (en) 2023-11-29
NZ732371A (en) 2023-04-28
PE20171179A1 (es) 2017-08-22
EP3677582A1 (en) 2020-07-08
ES2788454T3 (es) 2020-10-21
CN107108609A (zh) 2017-08-29
MX2017007162A (es) 2017-08-28
CA2970864C (en) 2020-04-14
JP6974534B2 (ja) 2021-12-01
JP2020143081A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
GEP20197050B (en) Solid state forms of fused heteroaromatic pyrrolidinones
FR22C1006I1 (fr) Derives de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak)
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PH12016500938A1 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
PH12016501232A1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
SI3322706T1 (sl) Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
PH12015502248A1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
NZ629230A (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ714742A (en) Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
HK1260275A1 (en) 2-aryl- and 2-heteroaryl-substituted 2-pyrtoazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
UA91310U (uk) [7-(4-МЕТОКСИФЕНІЛ)-5-(3,4-ДИМЕТОКСИФЕНІЛ)-2-ОКСО-3,5,6,7-ТЕТРАГІДРО-2Н-ТІОПІРАНО[2,3-d]ТІАЗОЛ-6-ІЛ]-ОКСОАЦЕТАТНА КИСЛОТА, ЩО ПРОЯВЛЯЄ АНТИЕКСУДАТИВНУ ДІЮ